Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele.

Clinical and experimental pharmacology & physiology - 1 Oct 2013

Pedersen Rasmus S, Noehr-Jensen Lene, Brosen Kim

Abstract excerpt

(1) The purpose of the present study was to examine whether cytochrome P450 2C19 (CYP2C19) in carriers of the CYP2C19*17 allele is inhibited in vivo by oral contraceptives (OC). (2) Retrospective CYP2C19 phenotyping according to omeprazole : 5-OH-omeprazole molar 3 h plasma metabolic ratios (MR) from a population (n = 222) genotyped as CYP2C19*1/*1, CYP2C19*1/*17 and CYP2C19*17/*17 was analysed. Furthermore, 30...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Contraceptives, Oral

Share to Cytochrome P-450 CYP2C19

Share to Gene Expression

Share to Heterozygote

Share to Omeprazole

Share to Proton Pump Inhibitors

Source

Identifiers

PMID: 23844835
DOI: 10.1111/1440-1681.12153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele.PMID 23844835Read ↗

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers.Semantic proximity Read ↗

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects.Semantic proximity Read ↗

Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population.Semantic proximity Read ↗

Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17.Semantic proximity Read ↗

CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy.Semantic proximity Read ↗

Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.Semantic proximity Read ↗

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Semantic proximity Read ↗

CYP2C19*17 is associated with decreased breast cancer risk.Semantic proximity Read ↗

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker.Semantic proximity Read ↗

Association between CYP2C19*17 and metabolism of amitriptyline, citalopram and clomipramine in Dutch hospitalized patients.Semantic proximity Read ↗

CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.Semantic proximity Read ↗

Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.